The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Cancer risks among BRCA1 and BRCA2 mutation carriers
Open accessAbstract
BRCA1 and BRCA2 mutations increase breast and ovarian cancer risks substantially enough to warrant risk reduction surgery, despite variable risk estimates. Underlying this variability are methodological issues, and also complex genetic and nongenetic effects. Although many modifying factors are unidentified, known factors can already be incorporated in individualised risk prediction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antoniou, A., Pharoah, P. D. P., Narod, S., Risch, H. A., Eyfjord, J. E., Hopper, J. L., Loman, N., Olsson, H., Johannsson, O., Borg, Å., et al. (2003) · The American Journal of Human Genetics · doi:10.1086/375033 · Cited by 3,680
Genetic Heterogeneity and Penetrance Analysis of the BRCA1 and BRCA2 Genes in Breast Cancer Families
Ford, D., Easton, D. F., Stratton, M., Narod, S., Goldgar, D., Devilee, P., Bishop, D. T., Weber, B., Lenoir, G., Chang-Claude, J., et al. (1998) · The American Journal of Human Genetics · doi:10.1086/301749 · Cited by 3,037
The Risk of Cancer Associated with Specific Mutations of BRCA1 and BRCA2 among Ashkenazi Jews
Struewing, J. P., Hartge, P., Wacholder, S., Baker, S. M., Berlin, M., McAdams, M., Timmerman, M. M., Brody, L. C., & Tucker, M. A. (1997) · New England Journal of Medicine · doi:10.1056/nejm199705153362001 · Cited by 2,281
Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2
King, M.-C., Marks, J. H., & Mandell, J. B. (2003) · Science · doi:10.1126/science.1088759 · Cited by 2,229
Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.
Easton, D. F., Ford, D., & Bishop, D. T. (1995) · PubMed Central · Cited by 1,602
Cancer Risks in BRCA2 Mutation Carriers
Breast Cancer Linkage Consortium, T. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.15.1310 · Cited by 1,527
Cancer Incidence in BRCA1 Mutation Carriers
Thompson, D. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.18.1358 · Cited by 1,096
Cancer Risk Estimates for BRCA1 Mutation Carriers Identified in a Risk Evaluation Program
Brose, M. S. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.18.1365 · Cited by 728
Wooster, R., & Weber, B. L. (2003) · New England Journal of Medicine · doi:10.1056/nejmra012284 · Cited by 605
Unusual case of Smith‐Lemli‐Opitz syndrome “type II”
Seller, M. J., Russell, J., & Tint, G. S. (1995) · American Journal of Medical Genetics · doi:10.1002/ajmg.1320560305 · Cited by 585
Understanding breast cancer risk - where do we stand in 2005?
Dumitrescu, R. G., & Cotarla, I. (2005) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2005.tb00350.x · Cited by 502
Variation in Cancer Risks, by Mutation Position, in BRCA2 Mutation Carriers
Thompson, D., & Easton, D. (2001) · The American Journal of Human Genetics · doi:10.1086/318181 · Cited by 489
Cancer risks in BRCA2 families: estimates for sites other than breast and ovary
van Asperen, C. J., Brohet, R. M., Meijers-Heijboer, E. J., Hoogerbrugge, N., Verhoef, S., Vasen, H. F. A., Ausems, M. G. E. M., Menko, F. H., Gomez Garcia, E. B., Klijn, J. G. M., et al. (2005) · Journal of Medical Genetics · doi:10.1136/jmg.2004.028829 · Cited by 420
Cancer Risks for Male Carriers of Germline Mutations in BRCA1 or BRCA2: A Review of the Literature
Liede, A., Karlan, B. Y., & Narod, S. A. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.055 · Cited by 407
Oral Contraceptives and the Risk of Breast Cancer in BRCA1 and BRCA2 Mutation Carriers
Narod, S. A. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.23.1773 · Cited by 380
Andrieu, N., Goldgar, D. E., Easton, D. F., Rookus, M., Brohet, R., Antoniou, A. C., Peock, S., Evans, G., Eccles, D., Douglas, F., et al. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj132 · Cited by 231
On the Use of Familial Aggregation in Population-Based Case Probands for Calculating Penetrance
Begg, C. B. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.16.1221 · Cited by 201
Andrieu, N., Easton, D. F., Chang-Claude, J., Rookus, M. A., Brohet, R., Cardis, E., Antoniou, A. C., Wagner, T., Simard, J., Evans, G., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.3126 · Cited by 188
Modifiers of risk of hereditary breast and ovarian cancer
Narod, S. A. (2002) · Nature Reviews Cancer · doi:10.1038/nrc726 · Cited by 179
Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers
Cullinane, C. A., Lubinski, J., Neuhausen, S. L., Ghadirian, P., Lynch, H. T., Isaacs, C., Weber, B., Moller, P., Offit, K., Kim‐Sing, C., et al. (2005) · International Journal of Cancer · doi:10.1002/ijc.21273 · Cited by 176
Self-citationOral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations
Whittemore, A. S., Balise, R. R., Pharoah, P. D. P., DiCioccio, R. A., Oakley-Girvan, I. A., Ramus, S. J., Daly, M. B., Usinowicz, M. B., Garlinghouse-Jones, K., Ponder, B. A. J., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602239 · Cited by 152
Milne, R. L., Knight, J. A., John, E. M., Dite, G. S., Balbuena, R., Ziogas, A., Andrulis, I. L., West, D. W., Li, F. P., Southey, M. C., et al. (2005) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-04-0376 · Cited by 135
Gillanders, W. E., & Simon, P. O. (2005) · The Women s Oncology Review · doi:10.1080/14733400500235731 · Cited by 123
Diet, lifestyle and BRCA-related breast cancer risk among French-Canadians
Nkondjock, A., Robidoux, A., Paredes, Y., Narod, S. A., & Ghadirian, P. (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9161-8 · Cited by 121
Narod, S. A., Lubiński, J., Ghadirian, P., Lynch, H. T., Møller, P., Foulkes, W. D., Rosen, B. P., Kim‐Sing, C., Isaacs, C. J., Domcheck, S., et al. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70624-6 · Cited by 112
BRCA1 and BRCA2 founder mutations and the risk of colorectal cancer.
Niell, B., Rennert, G., Bonner, J., Almog, R., Tomsho, L., & Gruber, S. (2004) · Journal of the National Cancer Institute · doi:10.1093/jnci/djh008 · Cited by 98
Simchoni, S., Friedman, E., Kaufman, B., Gershoni‐Baruch, R., Orr‐Urtreger, A., Kedar‐Barnes, I., Shiri‐Sverdlov, R., Dagan, E., Tsabari, S., Shohat, M., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0511301103 · Cited by 90
Self-citationAge at menarche and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers
Kotsopoulos, J., Lubiński, J., Lynch, H. T., Neuhausen, S. L., Ghadirian, P., Isaacs, C. J., Weber, B., Kim‐Sing, C., Foulkes, W. D., Gershoni‐Baruch, R., et al. (2005) · Cancer Causes & Control · doi:10.1007/s10552-005-1724-1 · Cited by 84
Self-citationContribution of Germline Mutations in BRCA2 , P16 INK4A , P14 ARF and P15 to Uveal Melanoma
Hearle, N., Damato, B. E., Humphreys, J., Wixey, J., Green, H. E., Stone, J. G., Easton, D. F., & Houlston, R. S. (2003) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.02-0026 · Cited by 72
Jernström, H., Loman, N., Johannsson, O. T., Borg, Å., & Olsson, H. L. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.03.035 · Cited by 71
Spurdle, A. B., Antoniou, A. C., Duffy, D. L., Pandeya, N., Kelemen, L., Chen, X., Peock, S., Cook, M. R., Smith, P. L., Purdie, D. M., et al. (2004) · Breast Cancer Research · doi:10.1186/bcr971 · Cited by 48
Research works printed but not linked: 3
- Gruber SB, Petersen GM (2002) Cancer risks in BRCA1 carriers: time for the next generation of studies. J Natl Cancer Inst 94: 1344–1345 · DOI
- Jernstrom H, Lubinski J, Lynch HT, Ghadirian P, Neuhausen S, Isaacs C, Weber BL, Horsman D, Rosen B, Foulkes WD, Friedman E, Gershoni-Baruch R, Ainsworth P, Daly M, Garber J, Olsson H, Sun P, Narod SA (2004) Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 96: 1094–1098 · doi:10.1093/jnci/djh211
- Spurdle AB, Antoniou AC, Kelemen L, Holland H, Peock S, Cook MR, Smith PL, Greene MH, Simard J, Plourde M, Southey MC, Godwin AK, Beck J, Miron A, Daly MB, Santella RM, Hopper JL, John EM, Andrulis IL, Durocher F, Struewing JP, Easton DF, Chenevix-Trench G, Australian Breast Cancer Family Study, Australian Jewish Breast Cancer Study, Breast Cancer Family Registry, Interdisciplinary Health Research International Team on Breast Cancer Susceptibility, The Kathleen Cunningham Foundation Consortium for Research into Familial Breast Cancer, Epidemiological Study of Familial Breast Cancer Study Collaborators (2006) The AIB1 polyglutamine repeat does not modify breast cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev 15: 76–79 · doi:10.1158/1055-9965.epi-05-0709
Cited by
Rapamycin fed late in life extends lifespan in genetically heterogeneous mice
Harrison, D. E., Strong, R., Sharp, Z. D., Nelson, J. F., Astle, C. M., Flurkey, K., Nadon, N. L., Wilkinson, J. E., Frenkel, K., Carter, C. S., et al. (2009) · Nature · doi:10.1038/nature08221 · Cited by 3,766
ATM and ATR as therapeutic targets in cancer
Weber, A. M., & Ryan, A. J. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.12.001 · Cited by 635
Vitale, A. V., Tan, H., & Jin, P. (2011) · Journal of Nucleic Acids Investigation · doi:10.4081/jnai.2011.2236 · Cited by 623
Liu, Y., Cao, Y., Zhang, W., Bergmeier, S., Qian, Y., Akbar, H., Colvin, R., Ding, J., Tong, L., Wu, S., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0131 · Cited by 555
The design of drugs for HIV and HCV
Clercq, E. D. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2424 · Cited by 430
Metadata
- Authors
- Levy-Lahad, E., & Friedman, E.
- Venue
- British Journal of Cancer
- Published
- 2007-01
- Volume
- 96
- Issue
- 1
- Pages
- 11-15
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W1968018827
- Cited by
- 327
- References
- 31
- FWCI
- 9.55
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.